Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 10.45
BTX's Cash-to-Debt is ranked lower than
58% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. BTX: 10.45 )
Ranked among companies with meaningful Cash-to-Debt only.
BTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 10.45
Equity-to-Asset 0.91
BTX's Equity-to-Asset is ranked higher than
72% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BTX: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
BTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -45.87  Med: 0.51 Max: 0.99
Current: 0.91
-45.87
0.99
Piotroski F-Score: 4
Altman Z-Score: 12.77
Beneish M-Score: -0.97
WACC vs ROIC
15.76%
-47.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1096.58
BTX's Operating Margin % is ranked lower than
76% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. BTX: -1096.58 )
Ranked among companies with meaningful Operating Margin % only.
BTX' s Operating Margin % Range Over the Past 10 Years
Min: -1262.63  Med: -533.84 Max: -116.83
Current: -1096.58
-1262.63
-116.83
Net Margin % 2358.68
BTX's Net Margin % is ranked higher than
99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. BTX: 2358.68 )
Ranked among companies with meaningful Net Margin % only.
BTX' s Net Margin % Range Over the Past 10 Years
Min: -989.69  Med: -341.59 Max: 2358.68
Current: 2358.68
-989.69
2358.68
ROE % 95.88
BTX's ROE % is ranked higher than
98% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. BTX: 95.88 )
Ranked among companies with meaningful ROE % only.
BTX' s ROE % Range Over the Past 10 Years
Min: -381.18  Med: -127.25 Max: 95.88
Current: 95.88
-381.18
95.88
ROA % 73.52
BTX's ROA % is ranked higher than
98% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. BTX: 73.52 )
Ranked among companies with meaningful ROA % only.
BTX' s ROA % Range Over the Past 10 Years
Min: -624.96  Med: -56.07 Max: 73.52
Current: 73.52
-624.96
73.52
ROC (Joel Greenblatt) % -822.79
BTX's ROC (Joel Greenblatt) % is ranked lower than
61% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. BTX: -822.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10626.09  Med: -2097.07 Max: -822.79
Current: -822.79
-10626.09
-822.79
3-Year Revenue Growth Rate -10.40
BTX's 3-Year Revenue Growth Rate is ranked lower than
68% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. BTX: -10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -51.6  Med: 6.15 Max: 106.8
Current: -10.4
-51.6
106.8
3-Year EBITDA Growth Rate -17.20
BTX's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BTX: -17.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.5  Med: 7.75 Max: 70.2
Current: -17.2
-48.5
70.2
GuruFocus has detected 6 Warning Signs with BioTime Inc $BTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BTX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BTX Guru Trades in

Q2 2015

BTX Guru Trades in Q2 2015

Jim Simons 165,000 sh (New)
» More
Q3 2015

BTX Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q1 2017

BTX Guru Trades in Q1 2017

Jim Simons 105,822 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:PTCHF, NAS:OVID, NAS:MRUS, NAS:BSTC, NAS:OTIC, OTCPK:THERF, NAS:AGEN, NAS:MCRB, NAS:ADXS, NAS:CLDX, NAS:PDLI, NAS:RXDX, NAS:CCXI, NAS:SYRS, NAS:BLCM, NAS:CRBP, NAS:NSTG, NAS:MYOK, NAS:GLYC, NAS:OCUL » details
Traded in other countries:BT3.Germany, BTX.Israel,
Headquarter Location:USA
BioTime Inc is a biotechnology company. The Company is engaged in the biomedical research and product development in regenerative medicine including human embryonic stem cell and induced pluripotent stem cell technology.

BioTime is a clinical-stage biotechnology company. Its objective is the development and commercialization of novel therapies developed with the help of the company's core technology platforms. The core therapeutic technologies are based on pluripotent stem cells that can become any of the cell types in the human body. Pluripotent stem cells have potential applications in many areas of medicine, including several age-related degenerative diseases and conditions for which there presently are no cures. The product portfolio includes Renevia, a potential treatment for HIV-related facial lipoatrophy; AST-VAC1, a cancer immunotherapy; and OpRegen, a potential therapy derived from pluripotent stem cells to treat the dry form of age-related macular degeneration.

Ratios

vs
industry
vs
history
PE Ratio 3.35
BTX's PE Ratio is ranked higher than
86% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. BTX: 3.35 )
Ranked among companies with meaningful PE Ratio only.
BTX' s PE Ratio Range Over the Past 10 Years
Min: 3.18  Med: 10.38 Max: 18.57
Current: 3.35
3.18
18.57
PE Ratio without NRI 3.35
BTX's PE Ratio without NRI is ranked higher than
87% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. BTX: 3.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
BTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.18  Med: 10.38 Max: 18.57
Current: 3.35
3.18
18.57
Price-to-Owner-Earnings 3.31
BTX's Price-to-Owner-Earnings is ranked higher than
84% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. BTX: 3.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.14  Med: 9.57 Max: 14.5
Current: 3.31
3.14
14.5
PB Ratio 1.92
BTX's PB Ratio is ranked higher than
58% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. BTX: 1.92 )
Ranked among companies with meaningful PB Ratio only.
BTX' s PB Ratio Range Over the Past 10 Years
Min: 1.82  Med: 9.83 Max: 45.12
Current: 1.92
1.82
45.12
PS Ratio 77.38
BTX's PS Ratio is ranked lower than
79% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. BTX: 77.38 )
Ranked among companies with meaningful PS Ratio only.
BTX' s PS Ratio Range Over the Past 10 Years
Min: 4.5  Med: 40.71 Max: 106.11
Current: 77.38
4.5
106.11
PEG Ratio 0.34
BTX's PEG Ratio is ranked higher than
71% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. BTX: 0.34 )
Ranked among companies with meaningful PEG Ratio only.
BTX' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: N/A
Current: 0.34
Current Ratio 3.32
BTX's Current Ratio is ranked lower than
63% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. BTX: 3.32 )
Ranked among companies with meaningful Current Ratio only.
BTX' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.74 Max: 76
Current: 3.32
0.02
76
Quick Ratio 3.32
BTX's Quick Ratio is ranked lower than
59% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. BTX: 3.32 )
Ranked among companies with meaningful Quick Ratio only.
BTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.71 Max: 74
Current: 3.32
0.02
74
Days Inventory 0.38
BTX's Days Inventory is ranked higher than
77% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BTX: 0.38 )
Ranked among companies with meaningful Days Inventory only.
BTX' s Days Inventory Range Over the Past 10 Years
Min: 0.38  Med: 44.57 Max: 97.03
Current: 0.38
0.38
97.03
Days Sales Outstanding 259.50
BTX's Days Sales Outstanding is ranked lower than
56% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. BTX: 259.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
BTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.3  Med: 88.57 Max: 259.5
Current: 259.5
71.3
259.5
Days Payable 2.00
BTX's Days Payable is ranked lower than
96% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. BTX: 2.00 )
Ranked among companies with meaningful Days Payable only.
BTX' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 1001.68 Max: 1789.56
Current: 2
2
1789.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.90
BTX's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. BTX: -21.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.3  Med: -13.95 Max: -2.1
Current: -21.9
-27.3
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 54.17
BTX's Price-to-Net-Cash is ranked lower than
99.99% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. BTX: 54.17 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.38  Med: 21.29 Max: 369
Current: 54.17
1.38
369
Price-to-Net-Current-Asset-Value 32.50
BTX's Price-to-Net-Current-Asset-Value is ranked lower than
100% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. BTX: 32.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.05  Med: 18.67 Max: 361
Current: 32.5
1.05
361
Price-to-Tangible-Book 2.02
BTX's Price-to-Tangible-Book is ranked higher than
62% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. BTX: 2.02 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.03  Med: 15.13 Max: 137.1
Current: 2.02
1.03
137.1
Price-to-Median-PS-Value 1.90
BTX's Price-to-Median-PS-Value is ranked lower than
73% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BTX: 1.90 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.13 Max: 32.6
Current: 1.9
0.12
32.6
Price-to-Graham-Number 0.55
BTX's Price-to-Graham-Number is ranked higher than
77% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. BTX: 0.55 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.55  Med: 1.31 Max: 1.75
Current: 0.55
0.55
1.75
Earnings Yield (Greenblatt) % -13.66
BTX's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. BTX: -13.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -31.84  Med: 0 Max: 0
Current: -13.66
-31.84
0

More Statistics

Revenue (TTM) (Mil) $4.24
EPS (TTM) $ 0.97
Beta2.23
Short Percentage of Float7.06%
52-Week Range $2.26 - 4.01
Shares Outstanding (Mil)110.88

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -0.46
EPS without NRI ($) -0.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime, Inc. breached its 200 day moving average in a Bullish Manner : BTX-US : May 25, 2017 May 25 2017
BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin... May 23 2017
BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) May 23 2017
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1 May 11 2017
BioTime Presents Retinal Restoration Data at ARVO May 11 2017
BioTime posts 1Q profit May 10 2017
BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments May 10 2017
Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised May 10 2017
Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View May 10 2017
BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD May 09 2017
BioTime, Inc. : Undervalued relative to peers, but don’t ignore the other factors May 08 2017
BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine... May 08 2017
BioTime, Inc. is trading below its 50 day moving average : BTX-US : May 5, 2017 May 05 2017
BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : May 2, 2017 May 02 2017
BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017 Apr 26 2017
BioTime to Present Additional Data at Upcoming ARVO Apr 24 2017
BioTime, Inc. is trading below its 50 day moving average : BTX-US : April 21, 2017 Apr 21 2017
BioTime, Inc. – Value Analysis (NYSE MKT:BTX) : April 20, 2017 Apr 20 2017
BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : April 19, 2017 Apr 19 2017
ETFs with exposure to BioTime, Inc. : April 13, 2017 Apr 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)